Thursday, August 18, 2005

MNTA

07:16 MNTA Momenta Pharma upped to $54 from $27 at ThinkEquity (25.56 +2.25) ThinkEquity raises their MNTA tgt to $54 from $27 as they believe MNTA's competitors (TEVA, Amphastar, and others) have little chance of gaining approval (0% probability). They do not believe the competitors have adequately characterized the active ingredients of either Lovenox or their products to satisfy regulatory requirements. Firm believes MNTA, by virtue of its superior polysaccharide characterization technology, may provide the FDA with information sufficient for approval (sole generic, 70% probability).

0 Comments:

Post a Comment

<< Home

Search Engine Submission and Search Engine Optimization

Disclaimer: This website may include stock market analysis. Any ideas or opinions expressed by us is for informational purposes. Trade at your own financial risk as we assume no responsibility for your investing decisions in the markets. Blogarama - The Blogs Directory BlogRankers.com Business Blog Top Sites TopBlog.ws - Top 
Blog, Directory and Search Engine <